Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evomela in AL Amyloidosis Patients Undergoing ASCT
NCT02994784Phase 2Terminated
- Sponsor
- Boston Medical Center
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in amyloid light chain amyloidosis, sponsored by Boston Medical Center. Primary endpoints: Number of Participants With Renal Dysfunction at 100 days and Number of Participants With Cardiac Dysfunction (New Arrhythmia) at 100 days. Started Jan 2018; status: terminated.
02
Drugs
melphalan
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02994784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994784.